Related references
Note: Only part of the references are listed.Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study
Diego R. Falci et al.
MYCOSES (2015)
Amphotericin B/Sterol Co-loaded PEG-Phospholipid Micelles: Effects of Sterols on Aggregation State and Hemolytic Activity of Amphotericin B
Thomas A. Diezi et al.
PHARMACEUTICAL RESEARCH (2012)
Amphotericin primarily kills yeast by simply binding ergosterol
Kaitlyn C. Gray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Pharmacokinetics and Nephrotoxicity of Amphotericin B-Incorporated Poly(Ethylene Glycol)-Block-Poly(N-Hexyl Stearate l-aspartamide) Micelles
Thomas A. Diezi et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Amphotericin B formulations and drug targeting
J. J. Torrado et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Enzymuria following amphotericin B application in the rat
G Inselmann et al.
MYCOSES (2003)
Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations
JD Cleary et al.
PHARMACOTHERAPY (2003)
Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity
ML Adams et al.
BIOMACROMOLECULES (2003)
Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures:: Animal experiments and clinical study
J Mayer et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Block copolymer micelles for the encapsulation and delivery of amphotericin B
A Lavasanifar et al.
PHARMACEUTICAL RESEARCH (2002)
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans
I Bekersky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Mortality and costs of acute renal failure associated with amphotericin B therapy
DW Bates et al.
CLINICAL INFECTIOUS DISEASES (2001)
Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
PJ Cagnoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
